Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

Jill Marie Broadfoot, the Chief Financial Officer of aTyr Pharma Inc (NASDAQ:ATYR), recently sold a portion of her holdings in the company. According to a recent SEC filing, Broadfoot sold 1,254 ...

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish Sati from the ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

However, pulmonary manifestations and symmetric oligoarthritis ... the most likely autoimmune disorder in this case is sarcoidosis. This multisystem granulomatous disorder can involve any organ ...

A breakthrough new AI model is able to detect the presence of different lung diseases from ultrasound videos, with 96.57% accuracy, and it is even able to distinguish whether the abnormalities are ...